Clinical Trials Logo

Fetal Lung Maturity clinical trials

View clinical trials related to Fetal Lung Maturity.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03562182 Recruiting - Clinical trials for Respiratory Distress Syndrome in Premature Infant

Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA

LPCAT1
Start date: June 18, 2018
Phase:
Study type: Observational [Patient Registry]

Neonatal respiratory distress syndrome affects babies who are born preterm and requires them to be placed on a ventilator in the Intensive Care Unit. Over 15 million babies were born premature and these numbers have been increasing. It is caused by lungs which are still too immature to produce adequate amounts of surfactant. This surfactant reduces the alveolar surface tension and maintains the alveoli from collapsing. Collapsed alveoli prevent gas exchange and greatly increase work of breathing. Surfactant is a biochemical complex made up mostly of phospholipids such as phosphatidylcholine and phosphatidylglycerol and these, in turn, appear to be synthesized by lysophosphatidylcholine acyltransferase 1 (LPCAT 1). The investigators have previously established that hLPCAT1 mRNA in maternal serum correlates with lamellar body count, a well established clinical marker of fetal lung maturity.